(Bloomberg) — Bayer AG won support from US regulators for a menopause drug that’s expected to hit the market in November under the name of Lynkuet.

The Food and Drug Administration approved the drug — also known by its chemical name elinzanetant — for treatment of women suffering from moderate to severe hot flashes related to menopause, Bayer said in a statement on Friday.

The medicine could help Bayer’s pharmaceutical division weather the sales decline in the coming years of blockbuster blood-thinner Xarelto, which is facing more competition from cheaper generic products.

The UK became the first country in the world to approve Lynkuet in July. It’s since been green-lighted in Australia, Canada, and Switzerland, and is pending approval in the European Union.

Bayer has developed the the

See Full Page